– Approval is based on Phase III INAVO120 results, showing the Itovebi TM (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the ...

CAMBRIDGE, Mass. and NEW YORK, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (BDTX) (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target ...

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the ...

AstraZeneca presented data from the AURA3 trial that data is supportive of Tagrisso (osimertinib) potentially becoming the new standard of care for 2nd-line treatment of patients with epidermal growth ...

First pivotal trial to demonstrate clinical value of monitoring circulating tumor DNA to detect and treat emerging resistance in 1st-line therapy ahead of disease progression in breast cancer First ...